Topics
CME/CE
Editorial Board
Oral tazarotene delivers lasting results
Washington -- Oral tazarotene (Tazorac; Allergan Inc., Irvine, Calif.,) gives patients with plaque psoriasis significant improvements that continue after treatment stops, according to a poster study presented at this year's annual meeting of the American Academy of Dermatology. The blinded, placebo-controlled, multicenter study of about 700 patients shows that oral tazarotene delivers several advantages over existing treatment alternatives.
Related Videos
Related Content
